Impact of Respiratory Bacterial Findings on Patients with Chronic Pulmonary Aspergillosis
Table 4
Comparison of clinical characteristics with and without any species of bacteria in sputum or bronchial washing fluid among study participants (N = 142).
Any species of bacteria
value
Yes
No
(n = 73)
(n = 69)
Age (years)
69 (63–76)
65 (57–73)
0.024
Sex (male)
41 (56.2)
53 (76.8)
0.013
Body mass index (kg/m2)
20.1 (17.9–22.8)
18.9 (16.9–21.5)
0.104
Underlying lung disease†
Previous history of pulmonary tuberculosis
50 (68.5)
47 (68.1)
>0.999
Nontuberculous mycobacterial pulmonary disease
27 (37.0)
21 (30.4)
0.479
Bronchiectasis
28 (38.4)
18 (26.1)
0.151
Emphysema
19 (26.0)
26 (37.7)
0.152
Interstitial lung disease
3 (4.1)
6 (8.7)
0.316
Previous history of thoracic malignancy
4 (5.5)
4 (5.8)
>0.999
Other comorbidities†
Diabetes mellitus
24 (32.9)
11 (15.9)
0.021
Congestive heart disease
7 (9.6)
4 (5.8)
0.534
Chronic hepatic insufficiency
4 (5.5)
5 (7.2)
0.740
Chronic renal insufficiency
3 (4.1)
4 (5.8)
0.713
Rheumatic disease
3 (4.1)
6 (8.7)
0.316
Previous history of extrathoracic malignancy
8 (11.0)
1 (1.4)
0.034
Chronic pulmonary symptoms†
Cough
36 (49.3)
26 (37.7)
0.179
Sputum
38 (52.1)
36 (52.2)
>0.999
Breathlessness‡
24 (32.9)
33 (47.8)
0.087
Hemoptysis
31 (42.5)
26 (37.7)
0.610
Chest computed tomographic findings†
Cavitation
73 (100)
69 (100)
NA
Paracavitary infiltrates
69 (94.5)
64 (92.8)
0.740
Mycetoma
20 (27.4)
21 (30.4)
0.715
Consolidation
3 (4.1)
9 (13.0)
0.072
Bilateral pulmonary lesions
18 (24.7)
19 (27.5)
0.707
Laboratory findings
White blood cells (μL)
8,130 (6,070−10,030)
7,580 (5,785−9,815)
0.431
C-reactive protein (mg/L)
8.9 (2.9–26.8)
13.8 (1.9–56.2)
0.422
Albumin (g/dL)
4.1 (3.6–4.4)
4.1 (3.5–4.4)
0.967
Data are presented as the median (interquartile range) or number (%). †Cases are duplicated. ‡Breathlessness represents a modified Medical Research Council dyspnea score ≥ 2. Bold values indicate statistical significance at P < 0.05.
